Introduction
RET, RCC, heterogenous malignancy
TUMOR GROWTH, METASTASIS, RCC
Renal cell carcinoma (RCC) is a heterogenous malignancy and the survival of patients with advanced and/or metastatic RCC is very poor [Cabozantinib is a receptor TKI with targets that include MET (c-MET), VEGFR2, RET, AXL, KIT, and TIE-2, which are implicated in tumor growth, metastasis, and angiogenesis [This phase 2 trial (ClinicalTrials.gov Identifier: NCT03339219) was designed to evaluate the efficacy and safety of cabozantinib in Japanese patients with RCC who met similar criteria to those who participated in the METEOR trial [Here, we update our previous report [